首页> 外文期刊>Infection and Drug Resistance >Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
【24h】

Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens

机译:达托霉素:一种针对革兰氏阳性病原体的新型脂肽抗生素

获取原文
获取外文期刊封面目录资料

摘要

Abstract: The aim of this review is to summarize the historical background of drug resistance of Gram-positive pathogens as well as to describe in detail the novel lipopeptide antibiotic daptomycin. Pharmacological and pharmacokinetic aspects are reviewed and the current clinical use of daptomycin is presented. Daptomycin seems to be a reliable drug in the treatment of complicated skin and skin structure infections, infective right-sided endocarditis, and bacteremia caused by Gram-positive agents. Its unique mechanism of action and its low resistance profile, together with its rapid bactericidal action make it a favorable alternative to vancomycin in multi-drug resistant cocci. The role of daptomycin in the treatment of prosthetic material infections, osteomyelitis, and urogenital infections needs to be evaluated in randomized clinical trials.
机译:摘要:这篇综述的目的是总结革兰氏阳性病原体耐药性的历史背景,并详细描述新型脂肽抗生素达托霉素。药理和药代动力学方面进行了审查,并提出了达托霉素的当前临床应用。达托霉素似乎是治疗由革兰氏阳性药物引起的复杂皮肤和皮肤结构感染,感染性右侧心内膜炎和菌血症的可靠药物。其独特的作用机理和低耐药性以及快速的杀菌作用使其成为万古霉素在多药耐药球菌中的理想替代品。达托霉素在修复性材料感染,骨髓炎和泌尿生殖道感染中的作用需要在随机临床试验中进行评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号